Evidence map›Paper›PMID 34959929›Full record

ArticleNutrients2021

Enhancement of the Anti-Angiogenic Effects of Delphinidin When Encapsulated within Small Extracellular Vesicles.

Merwan Barkallah, Judith Nzoughet-Kouassi, Gilles Simard, Loric Thoulouze, Sébastien Marze, Marie-Hélène Ropers, Ramaroson Andriantsitohaina

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Merwan BarkallahINSERM U1063, Université d'Angers, F-49000 Angers, France.
Judith Nzoughet-KouassiMitoLab, Unité MitoVasc, CNRS UMR 6015, INSERM U 1083, Université d'Angers, F-49000 Angers, France.ORCID 0000-0003-4987-1889
Gilles SimardINSERM U1063, Université d'Angers, F-49000 Angers, France.
Loric ThoulouzeINSERM U1063, Université d'Angers, F-49000 Angers, France.
Sébastien MarzeINRAE, Biopolymères Interactions Assemblages (BIA), F-44300 Nantes, France.
Marie-Hélène RopersINRAE, Biopolymères Interactions Assemblages (BIA), F-44300 Nantes, France.
Ramaroson AndriantsitohainaINSERM U1063, Université d'Angers, F-49000 Angers, France.ORCID 0000-0002-4770-3585
Inserm · FRCentre National de la Recherche Scientifique · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FR

Funding

Région Pays de la Loire 34000948
6 · The paper itself

Abstract

(1) Background: The anthocyanin delphinidin exhibits anti-angiogenic properties both in in vitro and in vivo angiogenesis models. However, in vivo delphinidin is poorly absorbed, thus its modest bioavailability and stability reduce its anti-angiogenic effects. The present work takes advantage of small extracellular vesicle (sEV) properties to enhance both the stability and efficacy of delphinidin. When encapsulated in sEVs, delphinidin inhibits the different stages of angiogenesis on human aortic endothelial cells (HAoECs). (2) Methods: sEVs from immature dendritic cells were produced and loaded with delphinidin. A method based on UHPLC-HRMS was implemented to assess delphinidin metabolites within sEVs. Proliferation assay, nitric oxide (NO) production and Matrigel assay were evaluated in HAoECs. (3) Results: Delphinidine, 3-O-β-rutinoside and Peonidin-3-galactoside were found both in delphinidin and delphinidin-loaded sEVs. sEV-loaded delphinidin increased the potency of free delphinidin 2-fold for endothelial proliferation, 10-fold for endothelial NO production and 100-fold for capillary-like formation. Thus, sEV-loaded delphinidin exerts effects on the different steps of angiogenesis. (4) Conclusions: sEVs may be considered as a promising approach to deliver delphinidin to target angiogenesis-related diseases, including cancer and pathologies associated with excess vascularization.

Indexed as

Angiogenesis InhibitorsDrug Delivery SystemsExtracellular VesiclesAnthocyaninsAortaCells, CulturedDendritic CellsDrug StabilityEndothelial CellsHumansNeovascularization, PathologicNitric OxideAngiogenesis InhibitorsAnthocyaninsdelphinidinNitric Oxideangiogenesiscancercardiovascular diseasesdelphinidinendothelial cellssmall extracellular vesicles

Identifiers

PMID34959929
PMCPMC8703615
OpenAlexW4200101420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.